Ki-Woong Nam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ki-Woong Nam has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Byung-Woo Yoon
Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Korea
1 shared publication - Eung-Joon Lee
Seoul National University Hospital, Seoul National University College of Medicine
1 shared publication - Han-Yeong Jeong
Emergency Medical Center, Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea
1 shared publication - Jeonghoon Bae
Department of Neurology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong-si, Republic of Korea
1 shared publication - Kipyoung Jeon
Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea
1 shared publication - Min Kyoung Kang
Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul 07804, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 6 March 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (3) , 337
Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke
Background: There is growing interest in the use of new biomarkers such as glycated albumin (GA), but data are limited in acute ischemic stroke. We explored the impact of GA on short-term functional outcomes as measured using the modified Rankin Scale (mRS) at 3 months compared to glycated hemoglobin (HbA1c). Methods: A total of 1163 AIS patients from two hospitals between 2016 and 2019 were included. Patients were divided into two groups according to GA levels (GA < 16% versus GA ≥ 16%). Results: A total of 518 patients (44.5%) were included in the GA ≥ 16% group. After adjusting for multiple covariates, the higher GA group (GA ≥ 16%) had a 1.4-fold risk of having unfavorable mRS (95% CI 1.02–1.847). However, HbA1c was not significantly associated with 3-month mRS. In addition, GA ≥ 16% was independently associated with unfavorable short-term outcomes only in patients without diabetes. Conclusions: In light of these results, GA level might be a novel prognostic biomarker compared to HbA1c for short-term stroke outcome. Although the impact of GA is undervalued in the current stroke guidelines, GA monitoring should be considered in addition to HbA1c monitoring.
- 6 March 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (3) , 337
Open AccessGlycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke
Background: There is growing interest in the use of new biomarkers such as glycated albumin (GA), but data are limited in acute ischemic stroke. We explored the impact of GA on short-term functional outcomes as measured using the modified Rankin Scale (mRS) at 3 months compared to glycated hemoglobin (HbA1c). Methods: A total of 1163 AIS patients from two hospitals between 2016 and 2019 were included. Patients were divided into two groups according to GA levels (GA < 16% versus GA ≥ 16%). Results: A total of 518 patients (44.5%) were included in the GA ≥ 16% group. After adjusting for multiple covariates, the higher GA group (GA ≥ 16%) had a 1.4-fold risk of having unfavorable mRS (95% CI 1.02–1.847). However, HbA1c was not significantly associated with 3-month mRS. In addition, GA ≥ 16% was independently associated with unfavorable short-term outcomes only in patients without diabetes. Conclusions: In light of these results, GA level might be a novel prognostic biomarker compared to HbA1c for short-term stroke outcome. Although the impact of GA is undervalued in the current stroke guidelines, GA monitoring should be considered in addition to HbA1c monitoring.